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Plasma levels of IL-113, TNFa and their specific inhibitors in undialyzed
chronic renal failure, CAPD and hemodialysis patients. The presence of
naturally occurring inhibitors of interleukin-1 (IL-l) and tumor necrosis
factor (TNF) in a variety of diseases has been demonstrated. The IL-i
receptor antagonist (IL-IRa) binds to IL-i receptors and blocks the
activity of IL-l, and a soluble form of the p55 TNF receptor
(TNF5Rp55) binds and neutralizes TNF. In the present study, plasma
levels of IL-l/3, IL-iRa, TNFa and TNFsRp55 were measured in 29
undialyzed patients with chronic renal failure (CRF), 13 patients on
continuous ambulatory peritoneal dialysis (CAPD), 42 patients on
chronic hemodialysis (HD) and in 15 healthy controls. Of the 29 patients
with CRF, 13 had end-stage renal disease (ESRD, estimated GFR < 10
mi/mm). Among healthy controls, plasma levels of IL-l/3, IL-IRa and
TNFa were at or below the limit of detection of the assay. In undialyzed
patients with ESRD, or in patients on CAPD or HD, plasma levels of
IL-i/3 were 428 134 pg/mi, 378 83 and 352 43 pg/mI, respectively.
Although plasma levels of IL-1f3 in each group of patients were higher
than those in healthy controls (<160 pg/mi), these differences were not
statistically significant. In contrast, plasma levels of IL-lRa in undia-
lyzed patients with ESRD (629 125 pg/mi, P = 0.03), CAPD (902
164 pg/ml, P < 0.0001) and HD patients (642 73 pg/ml, P = 0.004)
were significantly higher than those in healthy controls (103 15). In
the same groups, plasma TNFa levels were 1,419 434 pg/ml, 872
267 pg/mi and 803 241 pg/mI, respectively. Although plasma levels of
TNFx in all three groups of patients with chronic renal failure were also
higher than those in controls (<160 pg/mI), these differences were not
statistically significant. Plasma levels of TNFsRp5S in undialyzed
patients with ESRD, or in patients on CAPD or HD, were 12,754 2235
pg/ml, 13,373 1,815 pg/nil and 16,750 830 pg/mI, respectively.
These levels were significantly higher (P < 0.001) than those in healthy
controls (1,695 94pg/mI). The differences in IL-l/3, IL-IRa, TNFa or
TNFsRp55 between the three groups of patients were not statistically
significant. The molar ratios of plasma IL-lRa:IL-1j3 in ESRD, CAPD
and HD patients were 3 1, 4 I and 4 1, respectively. The molar
ratios of plasma TNFsRp55:TNFa ratios in these three groups were 13
3, 21 6 and 38 4, respectively. In undialyzed patients with CRF
and healthy controls, regression analysis showed a strong correlation
between serum creatinine and plasma levels of IL-iRa (r = 0.497, P =
0.001) or TNFsRp55 (r = 0.737,P < 0.0001). These results demonstrate
that plasma levels of IL-1p, TNFa and their specific inhibitors are
elevated in both undialyzed patients with ESRD as well as patients on
CAPD or HD. The elevated plasma levels of these proteins probably
reflect inadequate clearance as well as enhanced production.
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Patients on chronic hemodialysis often manifest anorexia,
wasting, accelerated atherosclerosis and /32 microglobulin amy-
loidosis. Although several causes contribute to these complica-
tions, a role for interleukin-lj3 (IL-1J3) and tumor necrosis factor
a (TNFa) has been proposed [1—4]. This concept is supported
by the observations that plasma levels of IL-1/3 and TNF can be
elevated in patients on chronic hemodialysis (HD), and that
peripheral blood mononuclear cells (PBMC) from these patients
often produce increased levels of IL-1f3 upon stimulation in
vitro [5—11]. Other investigators however, have failed to show
elevated IL-i or TNF in the plasma of HD patients, despite
using optimal methods of detection and extraction [12—14].
Interleukin- 1 and TNF production are accompanied by their
naturally occurring inhibitors [15—17]. Endogenous IL-i inhib-
itory activity had been observed in the circulation of human
volunteers injected with endotoxin [181 as well as in patients on
chronic hemodialysis [19]. The IL-I "inhibitor" purified from
urine was shown to block the binding of IL-i to its cell surface
receptor [15]. This IL-i inhibitor has since been cloned and
renamed IL-i receptor antagonist (IL-iRa) [20]. Increased
production of IL-iRa by blood cells has been demonstrated in a
variety of inflammatory conditions including patients on HD
[21].
Naturally occurring inhibitors of TNF have been identified
that block the cytotoxic and inflammatory actions of this
cytokine in vitro and in vivo [16, 17, 22]. Two such inhibitors
have been purified from human urine [23]. Amino acid sequence
analysis has shown that these inhibitors are the extracellular
domains of the two cell surface TNF receptors [24], and are
therefore termed TNF soluble receptors (TNFsR). There are
two TNFsR derived from p55 and p75 TNF cell surface
receptors. The TNFsRp55 is a cysteine rich glycoprotein with
identity to the extracellular portion of the p55 TNF receptor.
The TNFsRp75 is identical to the extracellular ligand-binding
domain of the p75 TNF receptor. Circulating levels of TNFsR
are elevated in several disease states including sepsis, menin-
gitis, autoimmunity, malignancy, allograft rejection, hairy cell
leukemia, type B chronic lymphocytic leukemia and HIV
infection [25—281.
In the present study, we measured the plasma levels IL-l/3,
IL-iRa, TNFa and TNFsRp55 in undialyzed patients with
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chronic renal failure, patients on chronic ambulatory peritoneal
dialysis and chronic hemodialysis. We also examined the ratio
between the plasma levels of pro-inflammatory cytokines and
their specific inhibitors, and the degree of renal insufficiency in
undialyzed patients with chronic renal failure.
Methods
Study population
Patients and controls. The study was approved by the
Human Investigation Review Committees of The New England
Medical Center and St. Elizabeth's Hospital. Informed consent
was obtained from each participant. Eighty-four patients with
chronic renal failure (CRF), between 20 and 80 years of age
were included in the study. Of these, 29 patients were undia-
lyzed (serum creatinine greater than 2.0 mg/dl), 13 patients were
on chronic ambulatory pentoneal dialysis (CAPD) and 42
patients were on chronic hemodialysis (HD). Of the 29 undia-
lyzed patients with CRF, 13 had end-stage renal disease
(ESRD, estimated GFR < 10 ml/min). The HD patients were
dialyzed three times a week with bicarbonate dialysate and
reused (average 20 reuses) cuprophan membranes (Clirans
C081, Terumo Corporation, Tokyo, Japan). The reuse proce-
dure included cleansing with reverse osmosis water, processing
with sodium hypochlorite (<1%) and disinfection with glutar-
aldehyde (0.8%) using an automated system (DRS 4TM Sera-
tronics Inc., Concord, California, USA). All dialysis patients
received human recombinant erythropoietin alpha (Epogen,
Amgen, Thousand Oaks, California, USA) to maintain hemat-
ocnt above 30%. Fifteen healthy volunteers, 20 to 50 years of
age and taking no medications, served as controls. Patients with
acute infection or blood transfusion in the past month, chronic
infections (hepatitis B, hepatitis C, human immunodeficiency
virus, etc), active immunological disease (systemic lupus ery-
thematosus, rheumatoid arthritis), immunosuppressive therapy
or malignancy were excluded from participation in the study.
Laboratory methods
Blood collection and assay. In patients on hemodialysis,
blood was drawn from the fistula needle immediately following
venipuncture prior to a routine hemodialysis session. In undi-
alyzed patients with chronic renal failure and patients on
CAPD, blood was drawn from a peripheral vein at the time of
routine laboratory investigations. Blood was drawn from a
peripheral vein in healthy controls. Blood was collected in
sterile, standard vacum blood collection tubes containing
EDTA (1.5 mglml of blood, Terumo Medical, Elktron, Mary-
land, USA). The tubes were immediately centrifuged (400 g, 10
mm). Plasma was removed without disturbing the buffy coat,
aliquots of 500 s1 were spun at 10,000 g for one minute at 4°C,
and stored at —70°C. Plasma levels of TNFa, IL-lRa and
glycosylated TNFsRp55 were measured by specific non-cross
reactive RIA [29—311. The presence of TNFa does not interfere
with the assay for TNFsRp55 [31] and the presence of TNF-
sRp55 does not interfere with the assay for TNFa [31]. For
IL-lp, plasma was subjected to two chloroform extractions [32,
331 before measurement by RIA. The limits of detection for
IL-l/3, IL-lRa, TNFa and TNFsRp55 RIA were 160 pglml, 80
pg/ml, 160 pglml and 160 pg/mI, respectively. In samples in
which the value was below the detection limit, the sample was
assigned a value equivalent to the detection limit.
Statistical analysis
Statistical analysis was performed using the SYSTAT soft-
ware package (SYSTAT Inc., Evanston, Illinois, USA). Anal-
ysis of variance (ANOVA) using Fisher's least significant
difference and the Tukey HSD test for simultaneous pair-wise
comparisons were employed to detect differences in plasma
cytokine levels between undialyzed patients with ESRD, CAPD
patients, HD patients and normal controls. In this analysis, only
patients with ESRD (serum creatinine greater than 6.0 mgldl)
were included to ensure comparable levels of residual renal
function. Simple regression analysis was employed to detect a
relationship between serum creatinine and plasma levels of
IL-lp, IL-iRa, TNFa and TNFsRp55, and was performed only
on results from normal controls and undialyzed patients with
varying degrees of CRF. Simple (Pearson) correlation was
employed to detect a relationship between plasma levels of
IL-1f3 and TNFa and their specific antagonists, and was per-
formed on results from healthy controls and all groups of
patients. Data are expressed as mean standard error of the
mean (sEM). The denominator for each cytokine varies because
adequate volume of plasma was not available for testing of all
cytokines and their inhibitors.
Results
Plasma levels of IL-I /3
Among healthy controls, plasma levels of IL-1f3 were consis-
tently below the limit of detection (160 pg/ml). In contrast,
plasma IL-l/3 levels were above 160 pg/mI in six of 13 (46%)
undialyzed patients with ESRD, 7 of 13 (54%) patients on
CAPD and 29 of 42 (69%) patients on HD. The plasma levels of
IL-l/3 in undialyzed patients with ESRD, CAPD and HD
patients were 428 134 pg/ml (range 160 to 1,700 pglml), 378
83 (range <160 to 1,200 pg/mI) and 352 43 pg/ml (range 160 to
1,700 pg/mI), respectively (Fig. 1). Although plasma levels of
IL- 1/3 in each group were higher than those in healthy controls
these differences were not statistically significant (P = 0.09).
The differences between the levels in undialyzed ESRD, CAPD
and HD patients were also not significant.
Plasma levels of IL-iRa
Plasma levels of IL- lRa were greater than 160 pg/ml in 2 of 12
(17%) healthy controls. In contrast, plasma IL-lRa levels were
above the lower limit of detection in each of 13 undialyzed
patients with ESRD, each of 13 patients on CAPD and each of
42 patients on HD. The plasma levels of IL-iRa in undialyzed
patients with ESRD, CAPD and HD patients were 629 125
pg/ml (range 300 to 2,100 pg/ml), 902 164 pg/mI (range 420 to
2,200 pg/ml) aqd 642 73 pg/ml (range 300 to 2,500 pg/ml),
respectively (Fig. 1). Plasma levels of IL-iRa in undialyzed
ESRD (P = 0.03), CAPD (P < 0.001) and HD (P = 0.004) were
significantly higher than those in healthy controls (103 15
pg/ml). However, the differences between undialyzed ESRD,
CAPD and HD were not significant. The molar ratios of plasma
IL-lRa:IL-l/3 ratio in undialyzed ESRD, CAPD and HD were 3
1, 3 1 and 4 1, respectively.
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Fig. 1. Plasma levels of IL-l/3 () and IL-iRa (LI) in normals, undia-
lyzed end-stage renal disease (ESRD), continuous ambulatory perito-
neal dialysis (CAPD) and hemodialysis (HD) patients. Plasma levels of
IL-l/3 were not significantly different between patient groups and
normals. Plasma levels of IL-IRa in ESRD (P = 0.03), CAPD (P <
0.001) and HD (P = 0.004) were significantly higher than those in
normals. However, the differences between ESRD, CAPD and HD
were not significant.
Plasma levels of TNFa
Plasma levels of TNFa were consistently below the limit of
detection (160 pg/mi) in healthy controls. In contrast, plasma
TNFa levels were greater than 160 pg/ml in 11(85%) of 13
undialyzed patients with ESRD, eight (67%) of 12 patients on
CAPD and 16 (38%) of 42 patients on HD. As shown in Figure
2, plasma levels of TNFa in undialyzed patients with ESRD,
CAPD and HD patients were 1,419 434 pg/ml (range 160 to
5,600 pg/ml), 872 267 pglml (range 160 to 3,400 pg/mI) and 803
241 pglml (range 160 to 6,800 pg/ml), respectively. Although
plasma levels of TNFn in each group of patients were higher
than those in controls, these differences were not statistically
significant (P = 0.14). The differences between undialyzed
ESRD, CAPD and HD were also not significant.
Plasma levels of TNFsRp55
Plasma levels of TNFsRp55 were above the detection limit of
160 pg/mI in both patients and controls. As shown in Figure 2,
the plasma levels of TNFsRpSS in undialyzed patients with
ESRD, CAPD, HD patients and healthy controls were 12,754
2235 pg/ml (range 3,300 to 32,000 pglml), 13,373 1,815 pg/mI
(range 1,250 to 27,000 pg/ml), and 16,750 830 pg/ml (range
8,500 to 28,000 pglml) and 1,695 94 pg/mI (range 1,100 to
2,350 pg/mI), respectively. Plasma levels of TNFsRpSS in
undialyzed ESRD (P < 0.001), CAPD (P < 0.001) and HD (P <
0.001) were significantly higher than those in healthy controls.
However, the differences between undialyzed ESRD, CAPD
and HD were not significant. The molar ratios of plasma
TNFsRp55:TNFn in undialyzed ESRD, CAPD and HD were 13
3, 21 6 and 38 4, respectively.
Normals ESRD CAPD HO
Fig. 2. Plasma levels of TNFa (0) and TNFsRp5S (LI) in normals,
undialyzed end-stage renal disease (ESRD), continuous ambulatory
peritoneal dialysis (CAPD) and hemodialysis (HD) patients. Plasma
levels of TNFs were not significantly different between patient groups
and normals. Plasma levels of TNFsRp55 in ESRD (P < 0.001), CAPD
(P < 0.001) and HD (P < 0.001) were significantly higher than those in
normals. However, the differences between ESRD, CAPD and HD
were not significant.
Correlation between plasma cytokine levels and serum
creatinine in undialyzed patients with chronic renal failure
and healthy controls
In undialyzed patients with chronic renal failure and healthy
controls, the correlation between serum creatinine and plasma
levels of cytokines/inhibitors was best with TNFsRp55 (r =
0.737, P < 0.001, Fig. 3D) followed by IL-iRa (r = 0.497, P =
0.001, Fig. 3B). The correlation between serum creatinine and
TNFa (r = 0.343, P = 0.03, Fig. 3C) or IL-1/3 (r = 0.045, F>
0.05, Fig. 3A) was poor.
Correlation between plasma levels of pro-inflammatory
cytokines and their specific inhibitors
In all groups of patients and healthy controls, the correlation
between plasma levels of IL-l/3 and IL-iRa (r = 0.042, P >
0.05), and TNFa and TNFsRpSS (r = 0.171, P > 0.05) was
poor.
Discussion
In this study, the measurement of plasma levels of IL-1/3,
TNFa and their specific inhibitors in the steady state revealed
that: (1) in undialyzed patients with ESRD, CAPD or HD,
IL-iRa and TNFsRp55 were significantly higher than those in
healthy controls; (2) levels of IL-1f3, IL-iRa, TNFa and
TNFsRpSS were not significantly different among the three
groups of patients with chronic renal failure; (3) among patients
with chronic renal failure, the molar ratios of plasma IL-iRa:
IL-1/3 ranged from 3:1 to 4:1 and the molar ratios of plasma
TNFsRp55:TNFs ranged from 13:1 to 38:1; (4) in undialyzed
patients with varying degrees of chronic renal insufficiency, the
plasma levels of both IL-lRa and TNFsRpS5 directly correlated
with the level of serum creatinine; and (5) the correlation
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Fig. 3. Correlation between plasma levels of IL-1/3 (A), IL-IRa (B), TNFa (C) and TNFsRpS5 (D), and serum creatinine in undialyzed patients
with chronic renal failure (N = 29) and healthy controls (N = 15). A. r = 0.045; P < 0.05. B. r = 0.497; P 0.001. C. r 0.343, P = 0.03. D. r =
0.737; P < 0.001.
between the plasma levels of IL-iRa and IL-lp, and TNFsRp55
and TNFa was poor.
Several investigators have observed that patients undergoing
chronic hemodialysis using regenerated cellulose membranes
have elevated circulating IL-i and TNF levels before a dialysis
session [5—7, 9, 10]. In addition, some studies have observed a
further increase in the plasma cytokine levels at the end of the
HD procedure [7]. Interestingly, undialyzed patients with
ESRD did not show evidence of elevated IL-i levels [7], leading
to the conclusion that the hemodialysis procedure itself, rather
than renal failure leads to increased IL-i production. However,
others have failed to show elevated IL-i or TNF in the plasma
of HD patients [12—14]. Consequently, the issue of whether
plasma cytokine levels are elevated during HD, particularly
during pyrogen reactions associated with HD, has been ques-
tioned by Powell and colleagues [13].
The failure to detect uniformly elevated levels of IL-1/3 in HD
patients could be due several factors. First, dialysis-induced
cytokine release may be transient. An example of this is
experimental endotoxemia in humans. Interleukin-l and TNF
are only transiently elevated (30 mm) after an injection of LPS
[34, 35]. Therefore, multiple, frequent measurements are sug-
gested for demonstrating elevated cytokines in the circulation
during disease [36]. Second, a significant proportion of the IL-i
synthesized remains intracellular and is not released into
plasma [30]. Third, poor nutrition and anemia in renal failure
and HD are associated with decreased cytokine production. In
fact, in HD patients treated with erythropoietin, there was a
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fivefold increase in the production of TNF, interferon, colony
stimulating factors, and IL-2 from mononuclear cells stimulated
in vitro [37]. Fourth, coexisting conditions such as acute and
chronic infections, autoimmune diseases, immunosuppressive
therapy, blood transfusions, etc., could influence the circulating
cytokine levels. Fifth, antihypertensive drugs such as angioten-
sin converting enzyme inhibitors and calcium channel blockers
suppress IL-i and TNF production in vitro [38]. Sixth, as in the
healthy population, there probably exists a wide spectrum in
the cytokine-inducing ability among dialysis patients, ranging
from low or normal to high. Indeed, we have observed a wide
variation in PBMC production of IL-lp among hemodialysis
patients [21]. Finally, the type of assay used and the technical
aspects of measuring cytokines could influence the levels ob-
served [33, 39].
The results of this study show that there were no significant
differences in the plasma levels of IL-1f3, TNFa, IL-IRa or
TNFsRp55 between undialyzed ESRD, CAPD or HD patients.
Similar results have been reported by Herbelin and colleagues
who found elevated plasma levels of TNFa and IL-6 in both
undialyzed patients with ESRD and patients on HD [7, 8].
Likewise, Brockhaus and colleagues have reported elevated
plasma levels of TNFsR in undialyzed patients with CRF as
well as HD patients [40]. An elevated plasma level of a cytokine
or its inhibitor in patients with renal insufficiency could be due
to increased production and/or decreased clearance. The
present study reveals a strong linear correlation between
plasma levels of IL-iRa, TNFsRp55 and serum creatinine.
Brockhaus and colleagues have also demonstrated a linear
correlation between plasma levels of TNFsR and serum creat-
mine in undialyzed patients with chronic renal failure [40]. This
correlation suggests that the kidney has an important role in the
metabolism and/or clearance of these molecules. Further, the
fact that the plasma levels of IL-1/3, IL-iRa, TNFa and
TNFsRp55 were not significantly different between undialyzed
ESRD, CAPD and HD patients suggests that these dialysis
modalities do not aid significantly in the clearance of these
proteins. However, studies in septic patients on CAVH with
polyacrilonitrile membranes have shown that TNFa is removed
from the circulation by adsorption to the membrane and to a
lesser extent by ultrafiltration [41]. This suggests that although
these proteins are to some extent cleared by dialysis, the
clearance may not match the natural excretion by the kidney.
A significant portion of the IL-i synthesized by activated
PBMC remains intracellular [42], and this intra-cellular IL-I
could serve as anjuxtacrine messenger. Further, IL-i levels at
the site of injury tend to be higher than those in circulation [43].
Indeed, monocytes disappear from the circulation within 15
minutes of the onset of dialysis [44, 45], show evidence of
activation [44], do not return to the circulation even after three
hours of dialysis [44], and probably are sequestered in the
microvessels of the lung, spleen or synovium. Consequently,
cytokines produced by these cells could exert their adverse
effects locally without getting access to the systemic circula-
tion. Therefore, plasma levels may not reflect the relative
production of these proteins by cytokine-producing cells.
In each group of patients with chronic renal failure, the
plasma levels of the specific inhibitory proteins were several-
fold higher than their specific cytokine counterparts. We have
previously shown that endotoxin-stimulated PBMC from undi-
alyzed patients with ESRD, CAPD or HD patients produced
significantly more IL-IRa than IL.i/3 [21]. These findings raise
the issue whether the levels of cytokine-specific inhibitors
observed in these patients are of functional significance or serve
as markers of inflammation. In vitro studies have shown that a
50- to 100-fold excess of IL-iRa is required to achieve 90%
inhibition of IL-i-induced responses in T cells, synovial cells
and chondrocytes [46,47]. In vivo, a 1000-fold excess of IL-iRa
is required to block the hemodynamic effects of IL-i [48]. In
animal models of disease, plasma levels of 10 to 20 sg/ml are
required to reduce the severity of disease [49]. The large molar
excess of IL-iRa required to block the biological effects of IL-i
in viva is explained by the fact that relatively low receptor
occupancy (5% or less) is sufficient to induce IL-i-mediated
effects [38, 49]. Therefore, it is unlikely that the plasma levels of
IL-iRa observed in this study are sufficient to block the
systemic effects of IL-I produced during dialysis.
Elevated levels of these inhibitory proteins are likely "foot-
prints" of IL-i and TNF. This conclusion is supported by the
observation that in critically ill patients with sepsis, plasma
IL-iRa levels correlated directly with APACHE II (Acute
Physiological and Chronic Health Evaluation) scores [50]. In
these inflammatory states, plasma levels of IL-iRa are at least
100-fold higher than those of IL-lp. This is likely to be due to
the fact that IL-iRa has a classical secretory leader sequence,
whereas IL-l13 and IL-la do not. Consequently, IL-Ra is
readily secreted by cells [30] compared to only 50% of IL-lp
and less than 10% of IL-la [30, 42, 51]. IL-lRa may therefore
be a circulatory marker of IL-l/3 production in the tissues.
As in the case of IL-iRa, in human volunteers given an
intravenous bolus of 3 ng/ml E. coli endotoxin, TNFsRp55
levels rose from baseline levels to a monophasic peak within 1.5
hours, followed by a plateau for an additional one hour and a
decline to pre-injection levels by 12 hours [31]. Likewise, in
human volunteers injected with 4 ng/ml E. coil endotoxin,
Spinas, Keller and Brockhaus have demonstrated a concurrent
rise of both TNFa and TNFsR [52]. Peak plasma levels of
TNFsR were observed 90 to 120 minutes after the TNFa peak,
were three- to eightfold higher than those of TNFa, and
elevated levels persisted longer than TNFa [52]. In individual
subjects, peak levels of TNFsRp75 correlated with those of
TNFa [52]. Human neutrophils and mononuclear cells shed
TNFsR upon stimulation [53], and elastase from the azurophilic
granules of leukocytes have been shown to cleave a 32 kDa
soluble fragment from the TNFRp75. Administration of TNFsR
to animals antagonizes the effects of TNF in viva, including
protection from lipopolysaccharide (LPS)-induced mortality in
mice [54]. However, the actions of TNFsR are more complex:
they can serve as TNF-inhibitors or as TNF-enhancers by
stabilizing the bioactive trimeric quaternary structure of TNFa
[55, 56]. As in the case of IL-iRa, the high plasma TNFsR
levels observed in patients with chronic renal failure are prob-
ably markers of inflammation [401.
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